ClinicalTrials.gg
CompletedNCT04528719Updated Aug 7, 2024

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

A Phase 1 interventional study of mRNA-1345 and Placebo in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 31 sites in United States. Open to participants aged 12 Months to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-07.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
651
Allocation
Randomized
Ages
12 Months to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.

Enrollment
5th of 10
651 · median 579
Started
2020
the only one that year
Phase 1
3 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
10 of 10
ModernaTX, Inc.

Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 5th largest by enrollment, is the only one that started in 2020, is one of 3 in phase 1, and was the 1st registered.

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.

Browse Virus Diseases studies →

Open to participants now

None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →

About mRNA-1345 respiratory syncytial virus vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.

This study: 12 Months to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases as a file.
02

Study summary

The primary objectives of this study are to evaluate the tolerability and reactogenicity of a single injection of up to 5 dose levels of mRNA-1345 in younger adults, women of child-bearing potential, and older adults including Japanese older adults; of 3 injections of the middle dose level of mRNA-1345 given 56 days apart in younger adults; of a booster injection of mRNA-1345 given approximately 12 and 24 months after the primary injection in older adults; and of 3 injections of 1 of 2 dose levels of mRNA-1345 given 56 days apart in children who are RSV-seropositive.

03

Conditions studied

  • Respiratory Syncytial Virus

Browse trials for

Keywords

  • Viral Diseases
  • Messenger RNA
  • Moderna
  • mRNA-1345
  • Respiratory syncytial virus
  • RSV Seropositive
  • Safety
  • Pediatric
  • Vaccines
04

Who can participate

Ages eligible
12 Months to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy young adults ≥18 to ≤49 years of age, women of ≥18 to ≤40 years of age, healthy older adults ≥65 to \<80 years of age, Japanese older adults ≥ 60 years of age, and children ≥12 to \< 60 months of age.
  • Willing and physically able to comply with protocol-mandated follow-up, including all procedures.
  • Adult participant or parent(s)/legal guardian(s) of pediatric participants has provided written for participation in this study, including all evaluations and procedures as specified by the protocol.

Specific inclusion criteria for adults (younger adults, women of child-bearing potential, and older adults [including Japanese older adults]):

  • Has a (BMI) from ≥18 kilogram (kg)/meter (m)\^2 to ≤35 kg/m\^2.
  • Female participants of non-child-bearing potential. This criterion does not apply for women of child-bearing potential Cohorts 12, 13, and 14.
  • Female participants of child-bearing potential may be enrolled in the study, if the participant: 1) has a negative urine pregnancy test at Screening and on the day of vaccination; 2) has practiced adequate or has abstained from all activities that could lead to pregnancy for 28 days prior to vaccination; 3) has agreed to continue adequate contraception through 3 months following the last injection; and 4) is not currently breastfeeding.

Specific inclusion criteria for children 12 to 59 months of age:

  • Seropositive for RSV-neutralizing Abs at Screening.
  • Has received routine immunizations appropriate for age per local guidance.
  • Current height and weight above the third percentile for age.

Specific inclusion criteria for Japanese older adults:

  • Japanese participants are defined as individuals born in Japan, with both parents and 4 grandparents who were born in Japan.

Key Exclusion Criteria:

  • Has Screening laboratory values Grade ≥1 (younger adult, women of child-bearing potential, and pediatric participants) or >Grade 1 (older adult participants, including Japanese older adult participants).
  • Is acutely ill or febrile on the day of the first injection.
  • Has a significant medical history, including but not limited to:

    • Congenital or acquired immunodeficiency, including (HIV) infection.
    • Chronic hepatitis or suspected active hepatitis.
    • Bleeding disorder that is considered a to intramuscular (IM) injection or phlebotomy.
    • Dermatologic conditions that could affect local solicited AR assessments.
    • Any history of allergic or anaphylactic reactions following a vaccination that required medical intervention.
    • disease except for Hashimoto's disease.
    • Systemic or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment. Topical tacrolimus is allowed if not used within 14 days prior to the day of enrollment. Inhaled, nasal, and topical are allowed.
    • Intravenous blood products (red cells, , and immunoglobulins [Ig]) within 3 months prior to enrollment.
  • Has received or plans to receive any licensed or authorized vaccine, to include COVID-19 vaccines, ≤ 28 days prior to the first injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after any study vaccine injection, with the exception of licensed influenza vaccines, which may be received more than 14 days before or after any study vaccine injection. Nonstudy vaccinations should not be delayed.
  • Has a history of myocarditis, pericarditis, or myopericarditis.

Specific exclusion criteria for older adults (Cohorts 7-11 and 15):

  • Known history of poorly controlled hypertension (per determination of the Investigator) or systolic blood pressure >160 millimeters of mercury (mmHg) at the Screening visit.
  • Known history of hypotension or systolic blood pressure \<85 mmHg at the Screening visit.
  • Poorly controlled diabetes mellitus (per determination of the Investigator).
  • Diagnosis of significant chronic pulmonary disease (per determination of the Investigator) (such as, , asthma).
  • Significant chronic cardiovascular disease (per determination of the Investigator).
  • Resides in a nursing home.
  • Anticipates the need for immunosuppressive treatment at any time during participation in the study.
  • Diagnosis of within previous 10 years (excluding non-melanoma skin cancer and cervical carcinoma in-situ).

Specific exclusion criteria for children 12 to 59 months of age (Cohorts 5 and 6):

  • Has received any monoclonal antibody at any time prior to Screening.
  • Prior hospitalization for RSV disease in the last 2 years.
  • Receipt of any prior systemic immunosuppressants or immune-modifying drugs.
  • Any history of febrile seizures (inclusive of single simple febrile seizure).
  • History of epilepsy.
  • History of meningitis.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
651 participants (actual)

Study arms

  • Experimental
    Cohort 1: Dose A in Younger Adults

    Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 2: Dose B in Younger Adults

    Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 3: Dose B in Younger Adults

    Three total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 4: Dose C in Younger Adults

    Single injection of Dose C of mRNA-1345 or matching-placebo on Day 1.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 5: Dose D in Children

    Three total injections, 1 injection of either Dose D of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 6: Dose G in Children

    Three total injections, 1 injection of either Dose G of mRNA-1345 or matching-placebo per day on Day 1, Day 57, and Day 113.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 7: Dose A in Older Adults

    Two total injections, 1 injection of either Dose A of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 8: Dose B in Older Adults

    Two total injections, 1 injection of either Dose B of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 9: Dose C in Older Adults

    Two total injections, 1 injection of either Dose C of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 10: Dose E in Older Adults

    Two total injections, 1 injection of either Dose E of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 11: Dose F in Older Adults

    Two total injections, 1 injection of either Dose F of mRNA-1345 or matching-placebo per day on Day 1 and approximately 12 months later. Participants will receive second booster injection of Dose A of mRNA-1345 at Month 24.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 12: Dose E in Women of Child-Bearing Potential

    Single injection of Dose E of mRNA-1345 or matching-placebo on Day 1.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 13: Dose F in Women of Child-Bearing Potential

    Single injection of Dose F of mRNA-1345 or matching-placebo on Day 1.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 14: Dose A in Women of Child-Bearing Potential

    Single injection of Dose A of mRNA-1345 or matching-placebo on Day 1.

    Biological: mRNA-1345 · Drug: Placebo

  • Experimental
    Cohort 15: Dose B in Japanese Older Adults

    Single injection of Dose B of mRNA-1345 or matching-placebo on Day 1.

    Biological: mRNA-1345 · Drug: Placebo

Interventions

  • BiologicalmRNA-1345

    Formulation for injection

  • DrugPlacebo

    0.9% sodium chloride (normal saline) injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Up to Day 737 (7 days after each injection)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 758 (28 days after the last injection)

  3. Number of Participants with Serious AEs or Medically Attended AEs (MAAEs)

    Time frame: Up to Day 1095 (End of Study)

Secondary outcomes

  1. Geometric Mean Titer (GMT) of Serum RSV Neutralizing and Binding Antibodies (Abs)

    Time frame: Up to Day 141 (Cohorts 5 and 6), up to Day 169 (Cohorts 1, 2, 4, 12, 13, 14, and 15), up to Day 281 (Cohort 3), and up to Day 1095 (Cohorts 7, 8, 9, 10, and 11)

  2. Geometric Mean Fold-Rise of Postbaseline/Baseline Ab Titers

    Time frame: Up to Day 141 (Cohorts 5 and 6), up to Day 169 (Cohorts 1, 2, 4, 12, 13, 14, and 15), up to Day 281 (Cohort 3), and up to Day 1095 (Cohorts 7, 8, 9, 10, and 11)

  3. Proportion of Participants with ≥2-fold and ≥4-fold Increases in Ab Titers from Baseline

    Time frame: Up to Day 141 (Cohorts 5 and 6), up to Day 169 (Cohorts 1, 2, 4, 12, 13, 14, and 15), up to Day 281 (Cohort 3), and up to Day 1095 (Cohorts 7, 8, 9, 10, and 11)

07

Study locations

31 sites
  • Paradigm Clinical Research Institute Inc - ClinEdge - PPDS
    La Mesa, California 91942-3189, United States
  • Mills Clinical Research
    West Hollywood, California 90046, United States
  • Accel Research Site - Angel Kids Pediatrics - ERN - PPDS
    DeLand, Florida 32720-0834, United States
  • Accel Research Sites - Nona Pediatric Center - ERN - PPDS
    Orlando, Florida 32806-2908, United States
  • Palm Beach Research - ClinEdge - PPDS
    West Palm Beach, Florida 33409-3401, United States
  • Centricity Research - Roswell - HyperCore - PPDS
    Columbus, Georgia 31904-8946, United States
  • IResearch Atlanta LLC
    Decatur, Georgia 30030-3438, United States
  • Velocity Clinical Research (Savannah - Georgia) - PPDS
    Savannah, Georgia 31406-2675, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814-4526, United States
  • Synexus - Optimal Research - Peoria
    Peoria, Illinois 61614, United States
  • Velocity Clinical Research (Sioux City - Iowa) - PPDS
    Sioux City, Iowa 51106-4233, United States
  • Michael W. Simon, M.D., PSC
    Nicholasville, Kentucky 40517, United States
  • Velocity Clinical Research (Lafayette - Louisiana) - PPDS
    Lafayette, Louisiana 70508-5173, United States
  • Velocity Clinical Research (Metaire - Louisiana) - PPDS
    Metairie, Louisiana 70006, United States
  • Velocity Clinical Research (Slidell - Louisiana) - PPDS
    Slidell, Louisiana 70458-5334, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Alliance for Multispecialty Research - Kansas City
    Kansas City, Missouri 64114-4866, United States
  • Velocity Clinical Research (Grand Island - Nebraska) - PPDS
    Grand Island, Nebraska 68803, United States
  • Velocity Clinical Research (Hastings - Nebraska) - PPDS
    Hastings, Nebraska 68901, United States
  • Velocity Clinical Research (Norfolk - Nebraska) - PPDS
    Norfolk, Nebraska 68701, United States
  • Velocity Clinical Research (Omaha - Nebraska) - PPDS
    Omaha, Nebraska 68134, United States
  • Velocity Clinical Research (Albuquerque - New Mexico) - PPDS
    Albuquerque, New Mexico 87102-3876, United States
  • Velocity Clinical Research (Binghamton - New York) - PPDS
    Binghamton, New York 13901-1046, United States
  • Velocity Clinical Research - Medford - ERN - PPDS
    Medford, Oregon 97504-9741, United States
  • Velocity Clinical Research - Columbia - PPDS
    Columbia, South Carolina 29204, United States
  • Velocity Clinical Research (Greenville - South Carolina) - PPDS
    Greenville, South Carolina 29615-4833, United States
  • Cyfair Clinical Research Center - ERN - PPDS
    Houston, Texas 77065, United States
  • Flourish Research - San Antonio - PPDS
    San Antonio, Texas 78229-3539, United States
  • DM Clinical Research
    Tomball, Texas 77375-6543, United States
  • Tanner Clinic
    Layton, Utah 84041, United States
  • Clinical Research Partners LLC
    Richmond, Virginia 23226-3787, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jul 2024, 45 months.

Of 28 industry-sponsored phase 1 interventional studies under Virus Diseases, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's 45 months is above that.

Counting every sponsor, half of 58 studies reached it within 24 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2020
First posted
Aug 27, 2020
StartActual
Sep 30, 2020
Primary completionActual
Jul 18, 2024
CompletionActual
Jul 18, 2024
Last update
Aug 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04528719
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Aug 27, 2020
Start date
Sep 30, 2020
Primary completion
Jul 18, 2024
Completion
Jul 18, 2024
Last update
Aug 7, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine

Start the discussion